ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2,1,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
2,2,Drug specific antibody,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
3,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
4,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
5,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
5,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
6,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
7,1,Abortion,Abortions not specified as induced or spontaneous,Abortions and stillbirth,Preg,N
7,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
8,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
8,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
9,1,Coagulation factor IX level increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
9,2,Coagulation factor VIII level increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
9,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
9,4,Fibrin D dimer increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
9,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
9,6,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
10,1,Hepatitis acute,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
11,1,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
11,2,Therapy change,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
12,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
12,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
12,3,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
12,4,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
13,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
13,2,Intentional underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
14,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
14,2,Migraine,Migraine headaches,Headaches,Nerv,N
14,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
15,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
15,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
15,3,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
15,4,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
15,5,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
15,6,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
15,7,Upper respiratory tract infection,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
16,1,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
17,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
17,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
17,3,Prophylaxis,Prophylactic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
18,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
19,1,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
20,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
20,2,Benign hydatidiform mole,Reproductive neoplasms female benign NEC,Reproductive neoplasms female benign,Neopl,N
20,3,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
20,4,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
21,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
22,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
23,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
24,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
24,2,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
25,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
26,1,Drug ineffective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
27,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
27,2,Ear infection,Ear infections,Infections - pathogen unspecified,Infec,N
27,3,Gestational diabetes,Pregnancy complicated by maternal disorders,Maternal complications of pregnancy,Preg,N
27,4,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
27,5,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
27,6,Sinusitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
28,1,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
29,1,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
30,1,Cardiac septal defect,Cardiac septal defects congenital,Cardiac and vascular disorders congenital,Cong,N
31,1,Fear of injection,Fear symptoms and phobic disorders (incl social phobia),Anxiety disorders and symptoms,Psych,N
31,2,Somatic symptom disorder,Somatic symptom disorders,Somatic symptom and related disorders,Psych,N
31,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
32,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
33,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
34,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
34,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
34,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
34,4,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
34,5,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
35,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
35,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
35,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
36,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
36,2,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
36,3,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
36,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
37,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
38,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
39,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
39,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
39,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
39,4,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
40,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
40,2,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
41,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
42,1,B-cell small lymphocytic lymphoma,B-cell small lymphocytic lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
42,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
42,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
42,4,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
43,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
43,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
43,3,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
44,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
44,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
44,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
44,4,Product supply issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
44,5,Product supply issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
45,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
45,2,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
45,3,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
45,4,Product supply issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
45,5,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
45,6,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
46,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
46,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
46,3,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
46,4,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
47,1,End stage renal disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
48,1,Coronavirus infection,Coronavirus infections,Viral infectious disorders,Infec,N
48,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
48,3,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
48,4,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
48,5,Product supply issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
48,6,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
49,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
49,2,Laryngeal oedema,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
50,1,Arterial injury,Cardiovascular injuries,Injuries NEC,Inj&P,N
50,2,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
50,3,Procedural complication,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
50,4,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
50,5,Surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
50,6,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
51,1,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
52,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
52,2,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
52,3,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
52,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
53,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
53,2,Product availability issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
54,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
55,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
55,2,Munchausen's syndrome,Factitious disorders,Somatic symptom and related disorders,Psych,N
56,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
57,1,Therapeutic response shortened,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
58,1,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
58,2,Prescription drug used without a prescription,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
58,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
59,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
59,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
59,3,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
59,4,Maternal exposure during breast feeding,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
59,5,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
59,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
60,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
61,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
61,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
61,3,Therapy change,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
61,4,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
62,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
62,2,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
63,1,Gallbladder operation,Biliary tract and gallbladder therapeutic procedures,Hepatobiliary therapeutic procedures,Surg,N
64,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
64,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
64,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
65,1,Hip surgery,Joint therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
66,1,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
66,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
66,3,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
66,4,Post procedural complication,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
66,5,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
67,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
67,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
68,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
68,2,Therapy change,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
68,3,Therapy change,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
68,4,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
69,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
69,2,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
69,3,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
69,4,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
69,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
69,6,Poor venous access,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
70,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
70,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
70,3,Drug ineffective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
70,4,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
70,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
71,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
71,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
71,3,Therapy change,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
72,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
72,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
72,3,Inadequate housing,Housing circumstances,Economic and housing issues,SocCi,N
72,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
72,5,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
72,6,Tooth extraction,Dental and gingival therapeutic procedures,Head and neck therapeutic procedures,Surg,N
73,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
73,2,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
73,3,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
73,4,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
73,5,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
73,6,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
73,7,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
73,8,Ear infection,Ear infections,Infections - pathogen unspecified,Infec,N
73,9,Ear pain,Ear disorders NEC,Aural disorders NEC,Ear,N
73,10,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
73,11,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
73,12,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
73,13,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
73,14,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
73,15,Mental impairment,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
73,16,Migraine,Migraine headaches,Headaches,Nerv,N
73,17,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
73,18,Nodule,Mass conditions NEC,Tissue disorders NEC,Genrl,N
73,19,Presyncope,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
73,20,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
73,21,Sleep inertia,Parasomnias,Sleep disorders and disturbances,Psych,N
73,22,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
73,23,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
73,24,Vascular access site complication,Cardiac and vascular procedural complications,Procedural related injuries and complications NEC,Inj&P,N
74,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
75,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
75,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
75,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
76,1,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
76,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
76,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
76,4,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
77,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
77,2,Product supply issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
78,1,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
78,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
79,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
79,2,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
79,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
80,1,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
81,1,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
82,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
83,1,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
84,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
85,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
86,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
86,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
87,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
87,2,Gallbladder polyp,Gallbladder disorders NEC,Gallbladder disorders,Hepat,N
88,1,Gallbladder disorder,Gallbladder disorders NEC,Gallbladder disorders,Hepat,N
89,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
89,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
89,3,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
89,4,Product distribution issue,Product distribution and storage issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
90,1,Fibromyalgia,Muscle pains,Muscle disorders,Musc,N
90,2,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
90,3,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
90,4,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
90,5,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
91,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
91,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
91,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
91,4,Intentional dose omission,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
91,5,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
91,6,Migraine,Migraine headaches,Headaches,Nerv,N
91,7,Muscle strain,"Muscle, tendon and ligament injuries",Injuries NEC,Inj&P,N
91,8,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
92,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
92,2,Hereditary angioedema,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
93,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
93,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
93,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
93,4,Poor venous access,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
94,1,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
94,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
94,3,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
94,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
94,5,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
95,1,Neoplasm,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
96,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
96,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
96,3,Product communication issue,Product transcribing errors and communication issues,Medication errors and other product use errors and issues,Inj&P,N
96,4,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
97,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
97,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
97,3,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
97,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
98,1,Hepatitis C virus test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
98,2,Suspected transmission of an infectious agent via product,Infectious transmissions,Ancillary infectious topics,Infec,N
98,3,Suspected transmission of an infectious agent via product,Infectious transmissions,Ancillary infectious topics,Infec,N
99,1,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
100,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
100,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
100,3,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
101,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
101,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
102,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
103,1,Ligament sprain,"Muscle, tendon and ligament injuries",Injuries NEC,Inj&P,N
104,1,Catheter site related reaction,Implant and catheter site reactions,Administration site reactions,Genrl,N
104,2,Injection site discomfort,Injection site reactions,Administration site reactions,Genrl,N
104,3,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
104,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
104,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
105,1,Weight abnormal,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
